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What Have We Learned About Patients With
Heart Failure and Preserved Ejection Fraction
From DIG-PEF, CHARM-Preserved, and I-PRESERVE?
Ross T. Campbell, MB CHB, BSC,* Pardeep S. Jhund, MB CHB, PHD,* Davide Castagno, MD,†
Nathaniel M. Hawkins, MB CHB, MD,‡ Mark C. Petrie, MB CHB, BSC,§ John J. V. McMurray, MD*
Glasgow, United Kingdom; Turin, Italy; and Liverpool, United Kingdom
Examination of patients with reduced and preserved ejection fraction in the DIG (Digitalis Investigation Group)
trials and the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) trials
provides comparisons of outcomes in each of these types of heart failure. Comparison of the patients in these
trials, along with the I-PRESERVE (Irbesartan in Heart Failure with Preserved Systolic Function Trial), with pa-
tients of similar age, sex distribution, and comorbidity in trials of hypertension, diabetes mellitus, angina pecto-
ris, and atrial fibrillation provides even more interesting insights into the relation between phenotype and rates
of death and heart failure hospitalization. The poor clinical outcomes in patients with heart failure and preserved
ejection fraction do not seem easily explained on the basis of age, sex, comorbidity, blood pressure, or left ven-
tricular structural remodeling but do seem to be explained by the presence of the syndrome of heart failure.
(J Am Coll Cardiol 2012;60:2349–56) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.064Because heart failure with preserved ejection fraction (HF-
PEF) is, in essence, a diagnosis of exclusion and because the
symptoms and signs of heart failure (of any type) are
nonspecific, there has been some doubt about the nature of
patients enrolled in clinical trials of HF-PEF (1,2). Com-
pared with those with heart failure and a reduced ejection
fraction (HF-REF), patients with HF-PEF are older, more
often female, and have a lower prevalence of coronary artery
disease (and higher prevalence of hypertension) (3–10). The
higher frequency of obesity (3) and chronic lung disease
(4,8) among patients with HF-PEF has even led to the
suggestion that these patients may be little more than
elderly, overweight women with swollen ankles who do not
have heart failure at all (11–14). Although patients with
HF-PEF were thought to have a similar prognosis to
patients with HF-REF (3,4), more recent studies have
suggested that they have a considerably better outcome
(15,16), further raising doubts about what the HF-PEF
syndrome really is or even whether it exists at all. Is this
skepticism justified? What can we learn from what hap-
pened to the patients enrolled in DIG (Digitalis Investiga-
tion Group)-REF and DIG-PEF (17,18), CHARM (Can-
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accepted April 16, 2012.desartan in Heart Failure: Assessment of Reduction in
Mortality and Morbidity)-REF and CHARM-Preserved
(19–21), and I-PRESERVE (Irbesartan in Heart Failure
with Preserved Systolic Function) trial (22,23) (Tables 1, 2,
and 3)? These programs include the 3 largest HF-PEF trials
to date, and all reported all-cause mortality and heart failure
hospitalization (HFH) rates per 1,000 patient-years of
follow-up, allowing comparison between these studies (and
with other trials).
HF-PEF Versus HF-REF
DIG and CHARM provide a unique opportunity to com-
pare and contrast patients with HF-REF and HF-PEF
because in both of these trials, centers enrolled patients with
each type of heart failure simultaneously. Comparison of the
baseline characteristics of patients with HF-PEF and HF-
REF in these trials confirms the differences noted in
epidemiological studies (e.g., patients with HF-PEF were
more often female, older, and more likely to have a history
of hypertension) (3,4). Another striking difference was in
the distribution of body mass index (and higher prevalence
of obesity) in patients with HF-PEF. The similar preva-
lence of diabetes but slightly higher prevalence of atrial
fibrillation is also consistent with results of epidemiological
studies (4,9,10). These patient differences were much more
prominent in the I-PRESERVE trial than in DIG-PEF or
CHARM-Preserved, probably because of differences in study
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teria, including entry ejection frac-
tion (EF) threshold.
CHARM-Preserved and
DIG-PEF Versus I-PRESERVE
The definition of preserved EF
differed between studies, with
DIG-PEF having an EF inclusion
of 45% (with a median of 53%
among randomized patients) (17)
and CHARM-Preserved having
n EF 40% (with a median of 52% among randomized
atients) (19). I-PRESERVE recruited only patients with
F-PEF and had the most stringent entry criteria (Table 1)
23). Although the inclusion EF threshold in I-PRESERVE
45%) was similar to DIG-PEF, the median EF of 59% in
-PRESERVE was considerably higher than in the other 2
tudies. The baseline characteristics also differed between
he HF-PEF trials; most notably, the prevalence of coronary
eart disease (Table 2). The low prevalence of coronary
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
EF  ejection fraction
HF-PEF  heart failure–
preserved ejection fraction
HF-REF  heart failure–
reduced ejection fraction
HFH  heart failure
hospitalization
Inclusion Criteria and Key Baseline Characteristics in HF-PEF and OTable 1 Inclusion Criteria and Key Baseline Characteristics in
Trial (Ref. #) Key Inclusion Criteria
DIG-PEF (17) HF-PEF
Age 21 years
LVEF 45%
Current/past symptoms/signs of HF or radiologic p
CHARM-Preserved (19) HF-PEF
Age 18 years
LVEF 40%
NYHA class II–IV
I-PRESERVE (23) HF-PEF
Age 60 years
LVEF  45%
NYHA class II–IV and HF hospitalization 6 month
and abnormal CXR, ECG, or echocardiogram
ACTION (24) Stable angina pectoris
Age 35 years
Proven CHD
ACCORD (25) Type II diabetes mellitus; HbA1c 7.5%
Age 40–79 years
CV disease/risk factors
ALLHAT (26) Hypertension
Age 55 years
1 CHD risk factor
ANBP-2 (27) Hypertension
Age 65–84 years
LIFE (28) Hypertension
Age 55–80 years
LVH (on ECG)
VALUE (31) Hypertension
Age 50 years
CV disease/risk factors
HYVET (32) Hypertension
Age 80 years
ACE  angiotensin converting enzyme; AF  atrial fibrillation; ACCORD  Action to Control Cardiovas
ntihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; ANBP-2  second
ssessment of Reduction in Mortality and Morbidity; CHD  coronary heart disease; CV  card
glycosylated hemoglobin; HF  heart failure; HF-PEF  heart failure–preserved ejection fraction; H
Systolic Function Trial; LIFE Losartan Intervention for Endpoint reduction in hypertension; LVEF left ven
VALUE  Valsartan Antihypertensive Long-term Use Evaluation.eart disease in I-PRESERVE may reflect the restriction
n use of angiotensin-converting enzyme (ACE) inhibitors
because ACE inhibition is indicated in patients with
oronary disease), although it is also consistent with the
pidemiological studies. Indeed, I-PRESERVE seems most
epresentative, overall, of patients with HF-PEF in the
ommunity (3–10), and CHARM-Preserved and DIG-
EF probably included a fraction of patients with left
entricular systolic dysfunction.
utcomes in HF-PEF and HF-REF
IG and CHARM provide a unique opportunity to com-
are outcomes in patients with HF-REF and HF-PEF, and
he rate of the same events (mortality and HFH), expressed
n the same manner (per 1,000 patient-years of follow-up),
s also available from I-PRESERVE.
The overall mortality rate was consistently higher in the
lacebo arms of CHARM-Alternative (20) (115 per 1,000
atient-years), CHARM-Added (21) (111 per 1,000
atient-years), and DIG-REF (18) (120 per 1,000 patient-
ears) compared with CHARM-Preserved (19) (54 per
Cardiovascular TrialsF and Other Cardiovascular Trials
Key Exclusion Criteria
ary congestion
AF or atrial flutter
Cor Pulmonale
Persistent systolic or diastolic hypertension
YHA class III/IV
AF with resting heart rate 120 beats/min
Cor Pulmonale
Clinically significant pulmonary disease
BP 160/95 mm Hg despite therapy
LVEF 40%
HF
LVEF 25%
Current symptomatic HF
NYHA class III/IV Congestive HF at any time
LVEF 35%
HF hospitalization or treated symptomatic HF
No HF/LVEF exclusion reported
LVEF 40%
HF
Congestive HF requiring ACE inhibitor therapy
HF requiring treatment with antihypertensive medication
sk in Diabetes; ACTION A Coronary disease Trial Investigating Outcome with Nifedipine; ALLHAT
an National Blood Pressure trial; BP  blood pressure; CHARM  Candesartan in Heart Failure:
lar; CXR  chest x-ray; DIG Digitalis Investigation Group; ECG  electrocardiogram; HbA1c 
Hypertension in the Very Elderly Trial; I-PRESERVE  Irbesartan in Heart Failure with PreservedtherHF-PE
ulmon
s or N
cular Ri
Australi
iovascu
YVET tricular ejection fraction; LVH left ventricular hypertrophy; NYHA New York Heart Association;
percut
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December 11, 2012:2349–56 Outcomes in HF-PEF1,000 patient-years) and DIG-PEF (17) (76 per 1,000
patient years) (Fig. 1). Mortality rates were somewhat
higher in both types of patients in DIG compared with
CHARM, perhaps reflecting improvements in the treat-
ment of cardiovascular risk factors and disease over the
period between DIG and CHARM. Despite the differences
in design, baseline characteristics, and median EF, the
mortality rate in I-PRESERVE (23) (53 per 1,000 patient-
years) was similar to that in CHARM-Preserved (54 per
1,000 patient-years); however, these rates were not adjusted
for age, sex, or difference in other prognostic variables
between trials. This lower mortality rate in patients with
HF-PEF is consistent with a recent individual-patient
meta-analysis of 41,972 participants in 31 cohort studies
and clinical trials (16). In that analysis, the mortality
difference persisted after adjustment for patient differences.
HFH rates showed a similar pattern, with much higher
rates in CHARM and DIG in those with HF-REF
(18,20,21) compared with patients in the same trials with
HF-PEF (17,19,23) (Fig. 2). Interestingly, I-PRESERVE
had an even lower rate of HFH than in CHARM-Preserved
and DIG-PEF.
Outcomes in Patients With HF-PEF
Versus Those in Other Cardiovascular Trials
Although the patients with HF-PEF in DIG and CHARM
clearly had better outcomes than those with HF-REF (as
Baseline Characteristics of I-PRESERVE, DIG, CTable 2 Baseline Characteristics of I-PRESE
Characteristic
DIG-REF (18)
(n  6,800)
DIG-PEF (17)
(n  988)
CH
Mean age (yrs) 64 67
Age 75 yrs (%) 15 23
Women (%) 23 41
Mean LVEF (%) 29 55
HF etiology (%)
Ischemic 71 56
Hypertensive 8.6 23
BMI (kg/m2) 27 29
BMI categories (%)
Underweight 2 2
Normal 34 26
Overweight 40 38
Obese 24 34
SBP (mm Hg) 126 138
Comorbidity (%)
Hypertension 45 60
Angina (current) 27 30
Myocardial Infarction 65 50
PCI/CABG — —
Atrial fibrillation NA NA
Diabetes 28 29
Stroke — —
Body mass index (BMI) categories: underweight18.5 kg/m2; normal
CABG  coronary artery bypass graft; NA  not available; PCI 
abbreviations as in Table 1.did patients in I-PRESERVE), how do they fare comparedwith women and men more generally? To look at this, we
compared the outcomes of patients with HF-PEF and those
enrolled in trials of other types of cardiovascular disease, in
which patients had similar age and sex profiles and similar
comorbidities. The most obvious comparator is trials of
older patients with hypertension, given that elevated blood
pressure is thought to be the major underlying etiology of
HF-PEF. Trials in patients with type 2 diabetes mellitus
and coronary heart disease also provide interesting compar-
isons. We identified such trials that reported heart failure as
an outcome and provided event rates per 1,000 patient-years
of follow-up (Tables 1 and 3) (24–32). All of the trials used
for comparison were large, randomized, and placebo con-
trolled. Several are notable. For example, 3 hypertension
trials enrolled a majority of women. The ANBP-2 (Second
Australian National Blood Pressure) trial (27) randomized
6,083 patients with a mean age of 72 years, 51% of whom
were female; the HYVET (Hypertension in the Very
Elderly Trial) (32) enrolled 3,845 patients with a mean age
of 84 years, 60% of whom were women. The Losartan
Intervention for Endpoint reduction in hypertension
(LIFE) (28) trial randomized 9,193 patients with a mean
age of 67 years; 54% were women. The mean ages of patients
in DIG-PEF, CHARM-Preserved, and I-PRESERVE were
67, 67, and 72 years, respectively, and the proportions of
women were 41%, 40%, and 60%. Systolic blood pressure
was higher in the hypertension studies than in the HF-PEF
-Preserved, and CHARM-REFDIG, CHARM-Preserved, and CHARM-REF
EF (20,21)
4,576)
CHARM-Preserved (19)
(n  3,023)
I-PRESERVE (23)
(n  4,133)
65 67 72
20 27 34
26 40 60
29 54 59
65 57 25
6.5 23 64
29 28 30
— — 0.5
32 23 16
41 39 42
27 38 41
127 136 136
49 64 88
(21) 53 (28) 40
58 44 24
5/25 19/22 13
26 29 29
29 28 27
9 9 10
24.9 kg/m2; overweight 25.0 to 29.9 kg/m2; and obese30 kg/m2.
aneous coronary intervention; SBP  systolic blood pressure; otherHARMRVE,
ARM-R
(n 
51
1
18.5 totrials, yet in all 3 of the hypertension trials, the mortality and
Baseline Characteristics in Other Cardiovascular Trials (Compared With HF-PEF Trials)Table 3 Baseline Characteristics in Other Cardiovascular Trials (Compared With HF-PEF Trials)
Characteristic
ACTION (24)
(n  7,665)
ACCORD (25)
(n  10,251)
ALLHAT (26)
(n  33,357)
ANBP2 (27)
(n  6,083)
LIFE (28–30)
(n  9,193)
VALUE (31)
(n  15,245)
HYVET (32)
(n  3,845)
DIG-PEF (17)
(n  988)
CHARM-Preserved (19)
(n  3,023)
I-PRESERVE (23)
(n  4,133)
Age (yrs) 63 62 67 72 67 67 84 67 67 72
Age 75 yrs (%) — — — 30 17 — 100 23 27 34
Women (%) 20 39 47 51 54 43 61 41 40 60
LVEF 57 — — — 61* — — 55 54 59
BMI (kg/m2) — 32.2 29.8 27 28 28.7 24.7 29 28 29.6
Obese (%) 23 — — — — — — 34 38 41
Heart rate (beats/min) 64 — — — 74 72 75 76 71 79
SBP (mm Hg) 137 136 146 168 174 155 173 138 136 136
DBP (mm Hg) 80 75 84 91 98 88 91 77 78 79
Creatinine (molL) — 80 78 — 86 101 89 111 99 88
Comorbidity (%)
Hypertension 52† — 100† 100 100 92 90 60 64 88
Angina pectoris 100 — 26‡ 8‡ 10 46‡ — 30 53 40
Myocardial Infarction 51 — — — 6 — 3 50 44 24
Atrial fibrillation — — — — 4 — — — 29 29
Diabetes 15 100 36 7 13 32 7 29 28 27
Stroke — — — 5§ 8 20 7 — 9 10
Treatment (%)
Diuretic 11 27¶ 46¶ 50 — — 50 76 75 83
Spironolactone — — — — — — — 8# 12 15
ACE inhibitor 20 53 27 50 — — — 86 19 25
ARB 2 — — — 50 50 — — 50 50
Beta-blocker 80 29 — — 50 — — — 56 59
CCB 50 — 27 — — 50 — — 31 40
Oral anticoagulant 4 — — — 1 — — — 25 19
Aspirin 86 55 36 — 21 — — — 59 55
Lipid-lowering agent 68 62** — 13 7 — — — 42 31
Values are mean unless otherwise stated. BMI categories: underweight 18.5 kg/m2; normal 18.5 to 24.9 kg/m2; overweight 25.0 kg/m2; and obese 30 kg/m2. *Echocardiography substudy. †BP 140/90 mm Hg. ‡Coronary heart disease. §Cerebrovascular disease.
Stroke or transient ischemic attack. ¶Thiazide diuretic. #Potassium-sparing diuretic. **Statin.
ARB  angiotensin receptor blocker; CCB  calcium channel blocker; DBP  diastolic blood pressure; HR  heart rate; other abbreviations as in Tables 1 and 2.
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December 11, 2012:2349–56 Outcomes in HF-PEFespecially the HFH rates were lower than in the HF-PEF
trials (Figs. 3 and 4). Only in the very elderly patients in
HYVET did mortality approach that of CHARM-
Preserved or I-PRESERVE, yet the rate of HFH was
between 8 and 13 times higher in the HF-PEF trials than
in HYVET. Inspection of the mortality and HFH rates
from the other trials provides a consistent message: patients
enrolled in the HF-PEF trials were at higher risk of death
and at strikingly higher risk of HFH than similar patients
with hypertension (and diabetes and angina pectoris, as
discussed in the following text).
The second Swedish Trial in Old Patients with Hyper-
tension (STOP-2) (33), which enrolled men and women
ages 70 to 84 years with systolic blood pressure 180 mm
Hg, diastolic blood pressure 105 mm Hg, or both, is also
of interest. The average age of the 6,614 randomized
subjects was 76 years; 67% were female. The STOP-2
investigators recorded the development of heart failure,
Figure 1 Overall Mortality in DIG, CHARM, and I-PRESERVE
Comparison of overall mortality rates between the heart failure–reduced ejec-
tion fraction trials (Digitalis Investigation Group [DIG]-REF, Candesartan in
Heart Failure: Assessment of Reduction in Mortality and Morbidity [CHARM]-
Added, and CHARM-Alternative) and heart failure–preserved ejection fraction
trials (DIG-PEF, CHARM-Preserved, and Irbesartan in Heart Failure with Pre-
served Systolic Function Trial [I-PRESERVE]).
Figure 2 Heart Failure Hospitalization
in DIG, CHARM, and I-PRESERVE
Comparison of heart failure hospitalization rates between heart failure–reduced
ejection fraction trials (DIG-REF, CHARM-Added, and CHARM-Alternative) and
heart failure–preserved ejection fraction trials (DIG-PEF, CHARM-Preserved, and
I-PRESERVE). Abbreviations as in Figure 1.whether requiring hospitalization or not, during a mean
follow-up of 5 years. The rate was 16.4 per 1,000 patient-
years in the conventional therapy (diuretic and beta-blocker)
group, and the rate of death from any cause was 33 per
1,000 patient-years. The incidence of heart failure thus still
remained much less than in the HF-PEF trials, even using
this much broader definition.
Finally, the Cardiovascular Health Study (CHS) offers
some perspective in relation to the mortality rates reported
in these trials. This population-based longitudinal study of
coronary heart disease and stroke recruited 5,888 persons
who were at least 65 years of age from the community in 4
U.S. states (34). The average age of the 4,684 subjects with
normal left ventricular systolic function and no heart failure
was 73 years, and 60% were women. Their rate of death per
1,000 patient-years of follow-up was 25; it was 87 in those
with HF-PEF (mean age 75 years; 56% female) and 154 in
patients with HF-REF (mean age 74 years; 37% female).
Figure 3 Overall Mortality in Cardiovascular and HF-PEF Trials
Comparison of overall mortality rates between cardiovascular trials (ACCORD
[Action to Control Cardiovascular Risk in Diabetes], second Australian National
Blood Pressure trial [ANBP-2], ACTION [A Coronary disease Trial Investigating
Outcome with Nifedipine], Losartan Intervention for Endpoint reduction in hyper-
tension [LIFE], VALUE [Valsartan Antihypertensive Long-term Use Evaluation],
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
[ALLHAT], and Hypertension in the Very Elderly Trial [HYVET]) and heart failure–
preserved ejection fraction (HF-PEF) trials (DIG-PEF, CHARM-Preserved, and
I-PRESERVE). Abbreviations as in Figure 1.
Figure 4 Heart Failure Hospitalization in
Cardiovascular and HF-PEF Trials
Comparison of heart failure hospitalization rates between cardiovascular trials
(ACCORD, ANBP-2, ACTION, LIFE, VALUE, ALLHAT, and HYVET) and HF-PEF trials
(DIG-PEF, CHARM-Preserved, and I-PRESERVE). Abbreviations as in Figures 1
and 3.
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Outcomes in HF-PEF December 11, 2012:2349–56These findings suggest that, as expected, the clinical trials
discussed earlier selected a relatively healthy and slightly
younger cohort, although, even taking this into account, the
patients in I-PRESERVE had a considerably higher mor-
tality than would be expected for subjects who were approx-
imately age and sex matched in the general population.
Unfortunately, the CHS has not reported HFH rates in
subjects with HF-PEF (35).
Cause of Death in Patients With HF-PEF
Versus Those in Other Cardiovascular Trials
Relatively few of the other cardiovascular trials give a
detailed breakdown of adjudicated cause of death (Table 4)
(36–38). Compared with trials in patients with hyperten-
sion, a considerably higher proportion of all deaths in
patients with HF-PEF was attributed to cardiovascular
causes (60% to 70% vs. 40% to 60%), particularly heart
failure and sudden death. A greater proportion of deaths in
patients with hypertension was attributed to stroke com-
pared with patients with HF-PEF.
Role of Other Comorbidities,
Particularly Atrial Fibrillation
Although the hypertension trials allow some indirect con-
trol for age, sex, and blood pressure when compared with
HF-PEF data, many had a low prevalence of diabetes
mellitus. This was not true, however, of either the
ALLHAT (Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial) (26) or the
VALUE (Valsartan Antihypertensive Long-term Use
Evaluation) trial (31); in the ACCORD (Action to Con-
trol Cardiovascular Risk in Diabetes) trial (25), in which all
enrolled patients had diabetes (Tables 1 and 3), the rates of
both mortality and HFH were much lower than in
I-PRESERVE (Figs. 3 and 4). Most of the hypertension
trials also had a low prevalence of coronary heart disease,
although the prevalence was similar in VALUE and I-
PRESERVE. Both VALUE (31) and ACTION (A Cor-
Cause of Death: Number of Patients (% of Total Mortality)Table 4 Cause of Death: Number of Patients (% of Total Morta
Factor
ALLHAT (26)
(n  33,357)
ANBP2* (27)
(n  6,083)
HYVET (32)
(n  3,845)
Total mortality 4727 405 431
CV mortality (%) 2193 (46.4) 166 (41.0) 220 (51.0)
Sudden death (%) — — 40 (9.2)†
Heart failure (%) 263 (5.6) 10 (2.5) 18 (4.1)
MI (%) 623 (13.2) 20 (4.9) 40 (9.2)†
Stroke (%) 370 (7.8) 44 (10.7) 69 (16.0)
Other CV death (%) 937 (19.8) 122 (30.1) 93 (21.6)
Non-CV (%) 2223 (47.0) 239 (59.0) 211 (49.0)‡
Unknown (%) 311 (6.6) — —
*92 coronary events in ANBP-2 (including MI, sudden death, other coronary deaths, and deaths a
§Unknown deaths assumed to be cardiovascular in CHARM-Preserved.
CV  cardiovascular; MI myocardial infarction; other abbreviations as in Table 1.onary disease Trial Investigating Outcome with Nifedipine)(24) (in which all patients enrolled had coronary heart
disease) reported a much lower mortality and HFH rates
than in I-PRESERVE (Figs. 3 and 4). The only comor-
bidity that is hard to account for in the comparator trials is
atrial fibrillation, which is a strong risk factor for HFH. It
is therefore useful to compare I-PRESERVE with the
ACTIVE-I (Atrial Fibrillation Clopidogrel Trial with Irbe-
sartan for Prevention of Vascular Events) (39) trial, which
enrolled 9,016 patients with atrial fibrillation and other
cardiovascular risk factors (including heart failure in 32%
and hypertension in 88%). The average age of randomized
patients was 70 years, and 39% were female. During a mean
follow-up of 4.1 years, the rate of heart failure events
(“HFH or other heart failure episodes”) was 32 per 1,000
patient-years in the placebo group, and the rate of death was
50 per 1,000 patient-years. Again, even using a broad
definition of heart failure in a particularly high-risk popu-
lation, the rate of heart failure events was one-half that in
DIG-PEF and CHARM-Preserved and lower than in
I-PRESERVE.
Cardiac Remodeling, Diastolic Function,
and Natriuretic Peptides
Whether cardiac remodeling, diastolic dysfunction, or both
explain the difference in outcome between patients with
HF-PEF and similar patients without HF-PEF is a key
question. Unfortunately, this question is presently unan-
swerable, as matched patients of each type have not under-
gone cardiac investigation using the same techniques. Nev-
ertheless, 1 non–HF-PEF trial, LIFE, is of interest as
electrocardiographic left ventricular hypertrophy was an
inclusion criterion in that trial. Probably as a result of this
requirement, patients in LIFE had a greater average left
ventricular mass than those in I-PRESERVE (as reported
in the echocardiographic substudies from these 2 trials) in
which left ventricular hypertrophy was not required at entry.
Despite this, patients in I-PRESERVE had much worse
(33)
,614)
DIG-PEF (17,36)
(n  988)
CHARM Preserved (37)
(n  3,023)
I-PRESERVE (38)
(n  4,133)
1 231 481 881
9.3) 162 (70.1) 340 (70.7) 532 (60.4)
4.8) 36 (15.6) 134 (27.9) 231 (26.2)
64 (27.7) 102 (21.2) 125 (14.2)
4.6) — 21 (4.4) 45 (5.1)
3.2) 7 (3.0) 33 (6.9) 76 (8.6)
6.7) 75 (32.5) 50 (10.4) 55 (6.2)
0.7) 55 (23.8) 141 (29.3) 268 (30.4)
14 (6.1) —§ 81 (9.2)
ed with coronary procedures). †MI and sudden death. ‡Noncardiovascular and unknown deaths.lity)
STOP2
(n  6
111
659 (5
164 (1
—
162 (1
147 (1
186 (1
452 (4
—
ssociatoutcomes (40,41).
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made, although the degree of diastolic dysfunction is a
predictor of outcome in patients with HF-PEF. It is
conceivable that patients with HF-PEF may have more
diastolic dysfunction than similar patients without HF-PEF
(41,42). This may also be relevant to the finding that
median N-terminal pro–B-type natriuretic peptide concen-
tration was much higher in I-PRESERVE (341 pg/ml;
interquartile range 135 to 974 pg/ml) than in LIFE (170
pg/ml; interquartile range 88 to 348 pg/ml), despite the
greater left ventricular mass in LIFE (43,44). Similarly,
while left ventricular mass in CHARM-Preserved was
similar to that in LIFE, median N-terminal pro-B-type
natriuretic peptide (344 pg/ml, interquartile range: 120 to
846 pg/ml) was twice that of LIFE (42). A better under-
standing of why N-terminal pro–B-type natriuretic peptide
is elevated to a greater extent in patients with HF-PEF than
in similar patients without is clearly important, given the
prognostic importance of this peptide in HF-PEF (45).
Study limitations. We only considered patients with HF-
PEF included in clinical trials (i.e., selected subjects), who
tend to be healthier than HF-PEF patients in the commu-
nity. However, this is also true of the patients enrolled in the
other comparator trials and, in that sense, we compared “like
with like.” We could only compare across trials and did not
have individual patient data. However, there was clearly
substantial overlap between the HF-PEF trials and the
others in key patient characteristics. The non–HF-PEF
trials largely excluded patients with symptomatic heart
failure, a low EF, or both. Like-with-like comparison of
structural remodeling and diastolic function is not possible,
and more subtle differences in systolic function have not
been examined (46).
Discussion
Although the entry criteria for DIG-PEF (17) and
CHARM-Preserved (19) have been criticized for being too
lax and although these trials have also been criticized for
selecting a healthy cohort as the result of their exclusion
criteria (1,2,14), it is clear that the patients enrolled had a
distinct clinical syndrome, HF-PEF, associated with a poor
prognosis. Although not as bad as patients with HF-REF,
the prognosis of patients with HF-PEF is substantially
worse than that of patients with hypertension and other
conditions that increase cardiovascular risk. What we have
learned from DIG, CHARM, and I-PRESERVE is that
HF-PEF is not just about old age, female sex, and high
blood pressure. Based on a comparison of 2 key trials, LIFE
and I-PRESERVE, the poor outcomes in patients with
HF-PEF may not be explained by left ventricular hypertro-
phy either. From the available data, the 2 things that most
clearly differentiate patients with HF-PEF from those with
hypertension is having the clinical syndrome of heart failure
(and often previous hospital admission with heart failure)
and elevated natriuretic peptide levels (47). We need tolearn more about the extent of diastolic dysfunction in
patients with HF-PEF compared with otherwise similar
patients without heart failure. Whatever the exact patho-
physiological basis of this syndrome, the diagnosis of heart
failure without a major reduction in EF clearly identifies a
patient at greatly elevated risk of HFH and premature
death.
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